Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies

NCT06034275 is registered in ClinicalTrials.gov with Vincerx Pharma, Inc. as lead sponsor.

NCT NCT06034275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06034275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
Lead sponsor
Vincerx Pharma, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 13, 2023
Completion date
December 31, 2025
Enrollment
36 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, b-cell acute lymphoblastic leukemia, high-risk myelodysplastic syndrome